Abstract: Oligoesters and polyesters comprising one or more (e.g., a plurality) of crosslinkable and/or crosslinked clickable groups (e.g., capable of or formed by click reactions, respectively). methods of making same. and uses of same. In various examples, a method forms objects by irradiating compositions comprising crosslinkable oligoesters and polyesters and, optionally, solvent (e.g., crosslink-able solvent), crosslinking reagent, and/or crosslinking initiator, with electromagnetic radiation and/or by heating the compositions. In various examples, a method forms films, fibers, and other 3D objects. In various examples, biodegradable and/or elastomeric materials comprising crosslinked oligoesters and polyesters are useful in devices (e.g., microfluidic devices, lab on a chip, drug delivery devices, and the like), scaffolds, tissue grafts, skin patches, and the like. In various examples, methods are additive manufacturing methods, (e.g., 3D printing methods, such as, for example, digital light processing (DLP)).

Abstract: An energy consumption decomposition method of an electric vehicle, an analysis method, a system, a device and a medium are provided, relating to the technical field of energy consumption monitoring of an electric vehicle. The energy consumption decomposition method includes: acquiring actual driving data of an electric vehicle to be analyzed during a trip; determining the trip energy consumption rate and driving features of the trip according to the actual driving data, where driving features of the trip are influenced by a trip factor and/or a driving behavior factor; and determining an energy consumption decomposition result of the electric vehicle according to driving features and the trip energy consumption rate, where the energy consumption decomposition result at least includes components of the energy consumption rate corresponding to driving features of the trip.

Abstract: Described herein are compositions of extracellular vesicles, and methods and systems of producing the extracellular vesicles. Also described herein are methods of using the extracellular vesicles.

Abstract: The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.

Abstract: The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.

Abstract: The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.

Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.

Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.

Abstract: The present invention provides a method for preparing dendritic cell loaded with antigen, the method comprising the steps of adding serum-free cell culture medium containing granulocyte-macrophage colony-stimulating factor (GM-CSF) and inter-leukin (IL)-4 into mononuclear cells, culturing in an incubator at 37° C. under 5% carbon dioxide for 5 days, adding target antigen wrapped cationic liposome and culturing for 8-24 hours to obtain target antigen loaded dendritic cell.